1. MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
- Author
-
Nassar, A.H., primary, Adib, E., additional, Kaldas, D., additional, Feng, J., additional, AbuAli, T., additional, Aredo, J., additional, Fitzgerald, B., additional, Bar, J., additional, Thummalapalli, R., additional, Parikh, K., additional, Whitaker, R., additional, Chen, L., additional, Harris, J., additional, Ayanambakkam, A., additional, Farid, S., additional, Owen, D., additional, Sharp, J., additional, Velazquez, A.I., additional, Ragavan, M., additional, D'aiello, A., additional, Cheng, H., additional, Piotrowska, Z., additional, Wilgucki, M., additional, Reuss, J.E., additional, Patil, T., additional, Nie, Y., additional, Baena Espinar, J., additional, Luders, H., additional, Grohe, C., additional, Sankar, K., additional, Nagasaka, M., additional, Ashara, Y.P., additional, Kwiatkowski, D.J., additional, Mak, R., additional, Amini, A., additional, Lobachov, A., additional, Lin, J.J., additional, Marron, T., additional, Yu, H., additional, Neal, J.W., additional, Wakelee, H.A., additional, Shepherd, F.A., additional, Dilling, T.J., additional, Gray, J.E., additional, Naqash, A.R., additional, Goldberg, S.B., additional, and Kim, S.Y., additional
- Published
- 2023
- Full Text
- View/download PDF